Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Daiichi Sankyo, NeoPharm, HLS Therap - LARVOL DELTA

Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis (ENDO 2025) - "The FDA recently approved resmetirom, a liver-directed β-selective thyroid hormone receptor agonist, for MASH with significant fibrosis...Treating mice with antisense oligonucleotides (ASOs) against Coenzyme A synthase (Cosay), Cell Death-inducing DNA fragmentation factor-like effector B (CideB), hydroxysteroid 17-beta dehydrogenase 13 (Hsd17b13) or treatment with bempedoic acid or atorvastatin decreased liver lipid droplet cholesterol content and prevented CDAHFD-induced MASH and the fibrotic response...Conclusions Our findings identify cholesterol in liver lipid droplets as a critical mediator of MASH and demonstrate that COASY, CIDEB, HSD17B13 knockdown and bempedoic acid are novel therapeutic approaches to reduce liver lipid droplet cholesterol content and thereby prevent the development of MASH and liver fibrosis. In addition, this mechanism broadly links to human MASH pathogenesis and is associated with gene variants, including PNPLA3 and HSD17B13."

Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • COL1A1 • PNPLA3

Access to Bempedoic Acid - A Real World Assessment in an Academic Clinical Practice (ENDO 2025) - "The most common reasons for denial or lack of initiation of BA were 1) the need for a trial of either ezetimibe or PCSK-9 inhibitor, 2) substantial co-pay, or 3) conditional approval for a year. Our real-world study confirms that BA is effective in achieving a significant reduction in LDL-C levels for up to a year and minimal side effects, similar to the previous efficacy studies. However, significant challenges due to insurance coverage remain, such as need for use of other LDL-C lowering agents and high co-pays that continue to limit patients' access to this medication."

Clinical • Real-world • Real-world evidence • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders • Musculoskeletal Pain • Pain • Type 2 Diabetes Mellitus

A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease. (clinicaltrials.gov) - P4 | N=379 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders

Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials. (PubMed, Atherosclerosis) - "Among available LLTs, PCSK9mAbs, inclisiran, CETPi, and niacin significantly decreased Lp(a) levels. Further research is necessary to understand whether this effect would translate into a clinically relevant cardiovascular benefit."

Journal • Retrospective data • Atherosclerosis • Cardiovascular

The GOLM1-ACLY pathway regulates macrophage-secreted EFEMP1 via H3K27ac modifications to drive tumor progression. (PubMed, J Adv Res) - "Our findings reveal a novel mechanism involving the GOLM1-ACLY axis within macrophages that regulates tumor progression, which suggest a potential strategy for tumor intervention."

Journal • Hepatocellular Cancer • Lung Cancer • Oncology • Solid Tumor • EFEMP1 • GOLM1

Shaping the dyslipidaemia treatment algorithm: real-world insights and the expanding role of bempedoic acid in oral triple therapy (ESC-WCC 2025) - "Sponsored by Daiichi Sankyo"

Clinical • Real-world • Real-world evidence • Cardiovascular • Dyslipidemia

Apparent Nonresponse to PCSK9 Inhibition in a Patient With Heterozygous Familial Hypercholesterolemia Due to PCSK9 Gene Duplication. (PubMed, JACC Case Rep) - "This case identifies PCSK9 gene duplication as a potential mechanism underlying nonresponse to PCSK9 inhibition and suggests that higher dosing of PCSK9 inhibitors may overcome nonresponse in some patients."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Gene Therapies • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Metabolic Disorders • PCSK9

A Call for Use of Lipid Fractionation Studies in Patients With Abnormal Standard Lipid Profiles. (PubMed, JCEM Case Rep) - "She was started on a triple cholesterol management regimen of ezetimibe, evolocumab, and bempedoic acid, which improved lipid fractionation values and symptoms. This case highlights the utility of using lipid fractionation studies in addition to traditional lipid panels to best treat patients with abnormal lipid panels on lipid-lowering therapy."

Journal • Asthma • Cardiovascular • Coronary Artery Disease • Dermatology • Diabetes • Dyslipidemia • Endocrine Disorders • Familial Hypercholesterolemia • Genetic Disorders • Hypoglycemia • Immunology • Metabolic Disorders • Myocardial Ischemia • Pain • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Vitiligo

Prediction of response to bempedoic acid in post-myocardial infarction patients followed in a Cardiac Rehabilitation Program (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular • Myocardial Infarction

Efficacy and safety of add on bempedoic acid on maximal dose of rosuvastatin and ezetimibe in patients with established coronary artery disease (ADDBAMPIRE study) (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular • Coronary Artery Disease

Shaping the dyslipidaemia treatment algorithm: real-world insights and the expanding role of bempedoic acid in oral triple therapy (ESC-WCC 2025) - "Sponsored by Daiichi Sankyo To discuss the role of bempedoic acid and oral lipid-lowering therapy in the management of dyslipidaemia Presenting real-world data on the efficacy and safety of oral triple therapy, assessing its sustainability."

Clinical • Real-world • Real-world evidence • Cardiovascular • Dyslipidemia

New treatments for dyslipidemia in older patients? Real-life analysis of the use of bempedoic acid in the elderly population. (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular • Dyslipidemia

Real-world effectiveness of bempedoic acid therapy on the reduction of low-density lipoprotein cholesterol levels in Germany (ESC-WCC 2025) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Cardiovascular • Dyslipidemia

Bempedoic acid does not affect skeletal muscle mitochondrial activity in hypercholesterolemic mice (ESC-WCC 2025) - No abstract available

Preclinical • Cardiovascular

Bempedoic acid in clinical practice. (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular

Frequency of gout adverse events with bempedoic acid or placebo in those receiving uric acid lowering therapies as prophylaxis or treatment after a gout episode - insights from CLEAR outcomes (ESC-WCC 2025) - No abstract available

Adverse events • Clinical • Cardiovascular

Advancing lipid management: insights from real-world evidence and combination therapy trials (ESC-WCC 2025) - "Discuss the efficacy and safety profile of bempedoic acid...Provide a hypothetical case study on the implementation of combination therapy. This Satellite Symposium has been organised and funded by Daiichi Sankyo and is intended for Healthcare Professionals only."

Clinical • Combination therapy • HEOR • Real-world • Real-world evidence • Cardiovascular

LDL-C targets after administration of the combination of bempedoic acid and ezetimibe in patients with acute coronary syndrome: an observational study with simulation analysis. (ESC-WCC 2025) - No abstract available

Clinical • Observational data • Acute Coronary Syndrome • Cardiovascular

Cardiovascular risk management beyond statins: review of new therapies available in Italy. (PubMed, Egypt Heart J) - "This review underscores the evolving landscape of lipid-lowering therapies, with emphasis on agents acting through novel mechanisms beyond statin pathways. Bempedoic acid, by inhibiting ACLY and increasing LDL receptor expression, represents a safe and effective option for reducing LDL-C, especially in statin-intolerant individuals. PCSK9 inhibitors further expand therapeutic options by augmenting LDL receptor recycling and clearance. The integration of these agents into clinical practice may help mitigate residual cardiovascular risk and personalize treatment strategies in dyslipidemia management."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • APOA1

The ACS EuroPath survey series: Time trends in lipid management after an acute coronary syndrome. (PubMed, Eur J Prev Cardiol) - "The survey shows earlier lipid assessment, increased combination therapy use, and improved LDL-C goal achievement over time. Training enhanced guideline adherence, emphasising the need for continuous efforts to achieve LDL-C goals."

Journal • Acute Coronary Syndrome • Cardiovascular

Impact of bempedoic acid on LDL-cholesterol management in patients with and without diabetes: insights from the MILOS study (EASD 2025) - P | "We aimed to analyze effect of BA/BA+ezetimibe (BA/BA+EZE) in patients with/without diabetes from 4 EU countries in the real-world MILOS study.Materials and MILOS, a prospective European study, assesses BA/BA+EZE effectiveness and safety in hypercholesterolemia/mixed dyslipidemia. MILOS data from 4 countries showed that adding BA/BA+EZE for 8 weeks, with or without other LLTs, led to ~7-fold increase in the proportion of diabetes and prediabetes patients achieving their LDL-C goal."

Clinical • Diabetes • Metabolic Disorders • Mixed Hyperlipidemia

High-sensitivity C-reactive protein and its role in coronary atherosclerotic disease: a review of current literature. (PubMed, Postgrad Med J) - "hsCRP is a valuable biomarker reflecting residual inflammatory risk in coronary atherosclerosis. Incorporating hsCRP into routine clinical practice may enhance cardiovascular risk stratification and guide therapeutic decisions."

Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Inflammation • CRP

Utilization and spending on lipid lowering therapies in Medicaid from 2018 to 2022. (PubMed, Am Heart J) - "Between 2018 and 2022, annual prescription fills for lipid lowering therapies in Medicaid remained stable while spending on these medications increased, driven by increased utilization of PCSK9 inhibitors, icosapent ethyl, and bempedoic acid. As Medicaid budgets face escalating financial pressure - and the burden of cardiovascular disease increases among low-income adults in Medicaid - it is critical that policymakers continue to monitor utilization and spending on existing and novel high-cost medical therapies."

Journal • Reimbursement • US reimbursement • Cardiovascular

Lipid lowering agents in solid organ transplant recipients. (PubMed, Nephrol Dial Transplant) - "The evolving evidence on combination therapy with statin and ezetimibe, novel PCSK9 modulators and bempedoic acid indicate, that LDL-C can be safely and efficiently reduced with improved adherence...Optimal lipid treatment targets in SOT recipients should be determined, depending on transplanted organ and CV risk category. We aimed to review current and future management of lipid disorders, propose an algorithm useful in clinical practice and call attention toward broader use of novel LLT along with further studies to assess their impact on clinical outcomes."

Journal • Cardiovascular • Dyslipidemia • Solid Organ Transplantation • Transplant Rejection • Transplantation

Triple Non-Statin Therapy with Ezetimibe, Inclisiran, and Bempedoic Acid in Patients with Genetically Confirmed Statin-Induced Rhabdomyolysis: A Dual Case Report. (PubMed, Pharmaceuticals (Basel)) - "In both patients, serial measurements of rosuvastatin plasma concentrations revealed markedly delayed elimination, with detectable levels persisting for several weeks despite ongoing dialysis. These two cases suggest that the combination of ezetimibe, inclisiran, and bempedoic acid may serve as a safe and effective therapeutic option in patients with severe statin intolerance. Pharmacogenetic testing and serial pharmacokinetic assessment may guide personalized lipid-lowering strategies and improve outcomes in this challenging patient population."

Journal • Acute Kidney Injury • Cardiovascular • Dyslipidemia • Metabolic Disorders • Nephrology • Renal Disease • ABCB1 • CYP2C9